# Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

> **NCT05833022** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 297 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05833022
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-30
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833022, "Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05833022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*